Literature DB >> 12121952

Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.

E Pérez-Trallero1, C García-Rey, A M Martín-Sánchez, L Aguilar, J García-de-Lomas, J Ruiz.   

Abstract

Six quinolones were tested on 817 consecutive pneumococcal isolates for which ciprofloxacin MICs were high (> or =2 microg/ml); the isolates had been collected during two recent Spanish surveillance studies. For strains for which the ciprofloxacin MIC was >or =4 microg/ml, the MICs at which 90% of the isolates tested against gemifloxacin, moxifloxacin, gatifloxacin, sparfloxacin, levofloxacin, and ofloxacin were inhibited were 0.25, 1, 1, 1, 4 and 16 microg/ml, respectively, and the corresponding prevalences of resistance were 0, 1, 4.5, 9.5, 8.4 and 23%. The proportion of isolates for which the ciprofloxacin MIC is high has increased over time.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121952      PMCID: PMC127368          DOI: 10.1128/AAC.46.8.2665-2667.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.

Authors:  F Fuentes; M J Giménez; F Marco; L Alou; L Aguilar; J Prieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-02       Impact factor: 3.267

2.  Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones.

Authors:  L Alou; M Ramirez; C García-Rey; J Prieto; H de Lencastre
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

3.  Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens.

Authors:  F Baquero; J A García-Rodríguez; J García de Lomas; L Aguilar
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

4.  The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.

Authors:  R Wise; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

5.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors:  D K Chen; A McGeer; J C de Azavedo; D E Low
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

6.  Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain.

Authors:  E Pérez-Trallero; C Fernández-Mazarrasa; C García-Rey; E Bouza; L Aguilar; J García-de-Lomas; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

  6 in total
  7 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.

Authors:  Emmanuelle Varon; Serge Houssaye; Sophie Grondin; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 3.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.

Authors:  María-Isabel Morosini; Elena Loza; Rosa del Campo; Felisa Almaraz; Fernando Baquero; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

5.  In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.

Authors:  Tsuyoshi Otani; Mayumi Tanaka; Emi Ito; Yuichi Kurosaka; Yoichi Murakami; Kiyomi Onodera; Takaaki Akasaka; Kenichi Sato
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

6.  Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B).

Authors:  Elia Gómez G de la Pedrosa; María-Isabel Morosini; Mark van der Linden; Patricia Ruiz-Garbajosa; Juan Carlos Galán; Fernando Baquero; Ralf René Reinert; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

7.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.